תדריך לעריכת קורות חיים...

1

Name: Dr. Shira Zelber-Sagi Date: February 2012

CURRICULUM VITAE

1. Personal Details

Name: Shira Zelber-Sagi

Date of Birth: March 9, 1974

Country of Birth: Israel

Identity Card Number: 02728738-2

Marital Status: Married and mother to Tom and Idan

Permanent Home Address: 5 Mosinson St. Tel Aviv 62965, Israel

Home Telephone Number: Tel: 972-3-5446086

Office Telephone Number: Tel: 972-3-5446086

Electronic Address: [email protected]

Fax Number: Tel: 972-3-5446086

2

2. Higher Education

A. Under graduate and Graduate Studies

Date of

Degree

Degree Name of Institution

and Department

Period of

Study

Sep 98 B.Sc Nutrition Sciences in the Agriculture Faculty,

Hebrew University

1995-

1998

August 07 Ph.D

Direct

course

Epidemiology and Preventive

Medicine, Sackler School of

Medicine, Tel Aviv University

2001-

2007

B. Post-Doctoral Studies

Since the graduation of the Ph.D I have been collaborating with senior

researchers from Israel and abroad. I have an ongoing cooperation with

two hospitals (besides the Tel-Aviv Sourasky Medical Center). The first

is with Prof Vlad Ratziu from Université Pierre et Marie Curie, Hôpital

Pitié Salpêtrière, Paris France in the subject of non-invasive assessment

of liver damage by biomarkers and the association with adipocytokines

in patients with fatty liver – a paper have been submitted. We also

compare different non-invasive methods for liver steatosis – the results

were presented in a conference by the European association for the study

of the liver and the paper is under preparation. Prof Ratziu and I also

wrote two literature reviews: one has been published and the seconds is

in print. I also have cooperation with Dr. Assy Nimer, Head, Liver

Clinic at Ziv Medical Center and Senior Lecturer at the Faculty of

Medicine, Technion Institute. I have initiated a clinical trial on the effect

of soft drinks in patients with fatty liver, which is ongoing.

3

3. Academic Ranks and Tenure in Institutes of Higher Education

2009- Lecturer at the School of Public Health, Faculty of Social Welfare and

Health Sciences, University of Haifa

4. Offices in University Academic Administration

*Responsible for research committee at the School of Public Health, Faculty of

Social Welfare and Health Sciences, University of Haifa.

5. Scholarly Positions and Activities outside the University

a. Professional Experience -

1999- Dietitian and Group manager. Sourasky Medical Center and Clalit Health

Services.

1999-2001- Manager of the nutrition field in "Mishan" Givataim geriatric

institute.

2006-07- Manager of internet nutrition forum for Clalit Health Services.

2009-2010 – Researcher responsible for the construction of a long term health

promotion program tailored for low socioeconomic population. The Samuel

Neaman Institute, the Technion.

b. Membership in professional associations

2000-2010 - The Israeli nutrition Association – ATID.

2002-2010 - The Israeli Association for the Study of the Liver.

2010 – The European Association for the Study of the Liver.

4

6. Participation in Scholarly Conferences

a. Active Participation

Subject of

Lecture/Discussion/Comments

Place of

Conference

Name of

Conference

Date No.

International Conferences

The prevalence of primary

nonalcoholic fatty liver disease

in the Israeli population and the

association with biochemical

and anthropometric measures.

Lisbon European

Association for the

Study of the Liver

09/04 1.

A double-blind randomized

placebo-controlled trial of

Orlistat for the treatment of

nonalcoholic fatty liver disease.

Boston American

Association for the

Study of Liver

Diseases

10/04 2.

Does weight loss improve liver

histopathology in nonalcoholic

fatty liver disease?

Paris European

Association for the

Study of the Liver

04/05

3.

Increased prevalence of


in patients with acute

myocardial infarction

independent of BMI.

San Francisco American

Association for the

Study of Liver

Diseases

11/05 4.

Is nonalcoholic fatty liver

disease an independent

predictor of the

Metabolic syndrome?

San Francisco American

Association for the

Study of Liver

Diseases

11/05 5.

Hyperinsulinemia is an San Francisco American 11/05 6.

5

independent predictor of

elevated serum ALT levels even

after adjustment to nonalcoholic

fatty liver disease and liver

histology.

Association for the

Study of Liver

Diseases

Serum ALT is not a

reliable screening tool for

nonalcoholic fatty liver

disease in the general

population.

Vienna European

Association for the

Study of the Liver

04/06 7.

Long term nutritional Intake

and the risk for Non-alcoholic

fatty liver disease; A population

based study.

Barcelona European

Association for the

Study of the Liver

04/07 8.

Role of physical activity in non-

alcoholic fatty liver disease

(NAFLD): A population based

study.

Boston American

Association for the

Study of Liver

Diseases

11/07

9.

A comparison between the

hepatorenal ultrasound index

and steatotest for the non-

invasive quantification of liver

steatosis

Milan European

Association for the

Study of the Liver

04/08 10.

Can serum leptin and

adiponectin predict liver injury

in patients with NAFLD? A

study in the general population

Copenhagen European

Association for the

Study of the Liver

04/09 11.

Discordance between three

successive Fibroscan

measurements mirrors the

Copenhagen European

Association for the

Study of the Liver

04/09 12.

6

variability of liver fibrosis

Effect of diet, exercise and anti-

obesity drugs on non-alcoholic

fatty liver disease. Invited

speaker and participant in a

panel discussion

Bologna European

Association for the

Study of the Liver

09/09 13.

A comparison of fatty liver

index with three non-invasive

methods for the detection and

Quantification of liver steatosis:

Regular ultrasound, hepatorenal

ultrasound index and steatotest

Vienna European

Association for the

Study of the Liver

*04/10 14.

The hepatorenal ultrasound

index is correlated with obesity,

ALT, insulin and

adipocytokines

Vienna European

Association for the

Study of the Liver

*04/10 15.

Case study: lifestylie

modification in a patient with

fatty liver.

Invited speaker.

Torino European

Association for the

Study of the Liver

Clinical School of

Hepatology:

Metabolic Liver

Diseases

*05/10 16.

Comparison of FibroTest to

other calculated scores for liver

fibrosis as a screening for

advanced nafld in the general

population.

Nice European

Association for the

Study of the Liver

*01/11

Is there an association between

coffee consumption and

NAFLD or presumed NASH

Nice European

Association for the

Study of the Liver

*01/11

7

and fibrosis in a general adult

population?

Incidence and regression rates

of NAFLD in seven years

follow up of a cohort from the

general population.

Berlin European

Association for the

Study of the Liver

*04/11

Metabolic and clinical aspects

of fructose, soft drinks, and

obesity-related disorders.

Invited speaker.

Athens,

Georgia

University of

Georgia global

health symposium

*09/11

Lifestyle and diet: What

evidence for impact on NAFLD

progression?

Invited speaker and a poster

chair.

Stockholm United European

Gastroenterology

Week

*10/11

Israeli Conferences

Role of noninvasive tests in the

classification of nonalcoholic

fatty liver disease

Eilat The Israeli

Association for the

Study of the Liver

12/02 1.

Factors modulating serum

alanine aminotransferase (ALT)

in patients with nonalcoholic

fatty liver disease.

Haifa The Israeli

Gastroenterology

Association

02/03

2.

Double blind randomized,

placebo-control trial of Orlistat,

for the treatment of primary


Herzliya The Israeli

Gastroenterology

Association

06/04 3.

Double blind randomized,

placebo-control trial of Orlistat,

for the treatment of primary


Tel-Aviv The Israeli

Association for the

Research and

Treatment of

06/04 4.

8

Obesity

Is NAFLD an independent

predictor of the metabolic

syndrome?

Eilat The Israeli

Association for the

Study of the Liver

02/05 5.

Nonalcoholic fatty liver disease

and hyperinsulinemia are major

determinants of serum ferritin

levels.

Eilat The Israeli

Association for the

Study of the Liver

03/06 6.

Role of physical activity in non-

alcoholic fatty liver disease

(NAFLD): A population based

study.

Tiberias The Israeli

Gastroenterology

Association

12/07 7.

A comparison between the

hepatorenal ultrasound index

and steatotest for the non-

invasive quantification of liver

steatosis

Eilat The Israeli

Association for the

Study of the Liver

03/08 8.

Discordance between three

successive Fibroscan

measurements mirrors the

variability of liver fibrosis

Kfar Blum The Israeli

Association for the

Study of the Liver

03/09 9.

A comparison of fatty liver

index with three non-invasive

methods for the detection and

Quantification of liver steatosis

Kfar Blum The Israeli

Association for the

Study of the Liver

03/10 10.

9

b. Organization of Conferences or Sessions

Subject of Conference/

Role at Conference/

Comments

Place of

Conference

Name of

Conference

Date

Updates in nutrition/

Chairperson and

organizer/ assembling

position statement on

behalf of ATID

Herzliya, Israel The Israeli dietitians

Association – ATID

professional

conference

11/08 1.

Nutritional treatment for

liver diseases/ Chairperson

and organizer

Tel-Aviv,

Israel

Nutrition Medical

Conference

*01/10 2.

Olive Oil and health,

scientific session

Jerusalem,

Israel

International Olive oil

conference

TERRAOLIVO

*05/11 3.

11

7. Invited Addresses

Presentation/Comments Name of Forum Place of

Lecture

Date

Physical activity

and nutrition for the

elderly

Geriatric

Medical

Conference

Tel-Aviv,

Israel

09/00 1.

Biochemical aspects and

pathogenesis of nonalcoholic

fatty liver disease

The Israeli Organization

of Medical Laboratories

Tel-Aviv,

Israel

01/03

2.

Nonalcoholic fatty liver

disease- a new old disease

Nutrition Medical

Conference

Tel-Aviv,

Israel

02/03 3.


disease

The Israeli family

physicians association

conference

Eilat, Israel 04/03 4.


disease in children

A pediatric conference in

the Tel Aviv Sourasky

Medical Center

Tel-Aviv,

Israel

07/03

5.

The epidemiology of

primary nonalcoholic

fatty liver

disease in Israel

The Israeli Association

for the Study of the Liver

Herzliya,

Israel

09/04 6.

The metabolic

syndrome,

MABAT from the liver

Nutrition Medical

Conference

Tel-Aviv,

Israel

01/05 7.

The nutritional

Treatment of

nonalcoholic fatty

liver disease

Nutrition Medical

Conference of Clalit

Health Services

Tel-Aviv,

Israel

11/05 8.

11

Vitamins and minerals Nutrition Medical

Conference

Ramat-

Gan, Israel

02/06 9.

Pediatric

nonalcoholic fatty

liver disease

Nutrition Medical


Health Services

Raanana,

Israel

08/07 10.

Nutritional anagement

In liver diseases

Conference by

"Hets"–The

Israeli association

for patients with

liver diseases

Tel-Aviv,

Israel

11/07 11.

The association between viral

hepatitis B & C and insulin

resistance

Nurses

conference

by "Schering-

Plough"

Tel-Aviv,

Israel

05/08 12.

What's between probiotics and

non-alcoholic fatty liver

disease

Nutrition Medical

Conference

Tel-Aviv,

Israel

05/08 13.

The association between egg

consumption and

cardiovascular disease -

Evidence Based Medicine

Nutrition Medical

Conference

Herzliya,

Israel

11/08 14.

The association between

soft drinks and fructose

consumption and obesity,

fatty liver and diabetes

Nutrition Medical


Health Services

Raanana,

Israel

05/09 15.

Effect of diet, exercise

and anti-obesity drugs on


disease

The Israeli Association

for the Study of the Liver

Ramat-

Gan, Israel

09/09 16.

Update in diet and physical

activity for the treatment of

NAFLD

Tel-Aviv, Israel Nutrition

Medical

Conference

*01/10 17.

12

Nutrition in viral liver

disease and cirrhosis

Nutrition Medical

Conference of Carmel

Hospital

Haifa,

Israel

*02/10 18.

Effect of olive oil in the

liver

International Olive oil

conference

TERRAOLIVO

Jerusalem,

Israel

*05/11 19.

8. Colloquium Talks

Presentation/Comments Name of Forum Place of

Lecture

Date

Clinical and

nutritional aspects of

nonalcoholic

fatty liver disease

Dept. of Nursing, Tel

Aviv University

Tel-Aviv,

Israel

11/02 1.

Case studies in nonalcoholic

fatty liver disease

Maccabi Healthcare

course for Family

Physicians

Ramat-

Gan,

Israel

06/04

2.

Nutritional management in


Nutrition trainee's course,

National Training Center,

Ministry of Health

Tel-

Hashomer,

Israel

05/06 3.

Nutritional treatment for

cirrhosis

Nutrition seminar of

Clalit Health Services

Tel-Aviv,

Israel

10/08 4.

Nutrition in the

Pathogenesis and

treatment of nonalcoholic

fatty liver disease

A conference for

physicians from eastern

Europe at the Tel Aviv

Sourasky medical center

Tel-Aviv,

Israel

12/08 5.


soft drinks and fructose

consumption and obesity,

fatty liver and diabetes

Nutrition Medical


Health Services

Raanana,

Israel

05/09 6.

13

Nutrition in the

pathogenesis and


fatty liver disease

Gastroenterology course

for medical students at

the Tel-Aviv University

(the 4 years program)

Tel-Aviv,

Israel

*03/10 7.

Nutrition in the

Pathogenesis and


fatty liver disease

A conference for

physicians from

Kazakhstan at the Tel

Aviv Sourasky medical

center

Tel-Aviv,

Israel

*07/10 8.

Role of nutrition in liver

Andcardiovascular

diseases

Nutrition seminar of

Maccabi Healthcare

Ramat-

Hasharon,

Israel

*07/10 9.

Nutrition and obesity in

view of public health and

primary prevention

Health promotion course

for 6th

year medical

students at the Tel-Aviv

University

Tel-Aviv,

Israel

*10/10 10.

Nutrition in the

pathogenesis and


fatty liver disease

Gastroenterology course

for medical students at

the Tel-Aviv University

(the 4 years program)

Tel-Aviv,

Israel

*03/11 11.

9. Research Grants

a. Grants Awarded

In all grants awarded the entire fund amount was assigned to me.

Year Funded by Topic Co-Researchers Role in

Research

2002

Tnuva Research

Fund.

000000 NIS


calcium intake and the

metabolic syndrome

Prof. Ran Oren Co-PI

2002 Research fund

of the Institute

for the Research

The Prevalence of


fatty liver disease in the

Prof. Ran Oren PI

14

of the Influence

of Food on

Human Health

and Quality of

Life.

200000 NIS

Israeli population and the

association with

biochemical and

anthropometric

measures.

Papers: See publication

number 2

2002 Chief Scientist

Office, Ministry

of Health,

feasibility study.

25,000 NIS


treatment with drugs

inhibiting the renin–

angiotensin (RAS)

system and the rate of


disease in type-2 diabetic

patients

Prof. Ran Oren

Dr. Hanny Yeshua

*Co-PI

2000 Pfizer research

grant.

10,000 NIS

Screening policy for

cardiovascular disease in

Israel: should Non-HDL

cholesterol be routinely

included in risk

assessment and in the

indications for medical

treatment?

Dr. Hanny Yeshua

Samah Haiek

*PI

2011 Pfizer research

grant.

10,000 NIS

Trends in serum

25(OH)D distribution in

the Israeli population in

the last decade

Prof. Tamar Shohat *PI

b. Submission of Research Proposals – Pending

Year Funded by Topic Co-Researchers Role in

Research

2000 Deutsche

Forschungsgemei

nschaft Trilateral

Projects

Ethnic and clinical

differences in Non-

alcoholic fatty liver

disease (NAFLD): A

prospective study in three

diverse populations

Dr. Oren Shibolet

Prof. Ziad Abdeen Prof. Manfred Green

Prof. Michael Manns Prof. Heiner

Wedemeyer

*PI

2011 Italy-Israel

Cooperation

Scientific grant

Association among

Advanced Glycation End

Products, Cytokines and

dietary habits in patients

with non-alcoholic fatty

liver disease

Prof. Fabio Galvano *Co-PI

15

c. Submission of Research Proposals – Not Funded

Score Year Funded by Topic Co-Researchers Role in

Research

- 2010 Pre-

proposal for

the Middle

East

Regional

Cooperation

Program

(MERC).

598,000 $

Detection and treatment

of non-alcoholic fatty

liver disease as a means

of controlling the

epidemic of diabetes

mellitus in the Israeli

and Palestinian

populations

Dr. Arafeh Nabil

Dr. Raed Titi

Prof. Manfred Green

Prof. Ran Oren

*PI

- 2000 Pre-

proposal for

the

MINERVA

Center.

€150,000

per year

Establishment of a

center on biological,

clinical and public

health aspects of liver

diseases and obesity

Prof. Manfred

Green

Prof. Heiner

Wedemeyer

Prof. Ran Oren

*Co-PI

- 2010 Pfizer

research

grant.

10,000 NIS

Building evidence to

public health policy

aimed at reduction of

soft drinks consumption

Hala Nseir

Dr. Assy Nimer

*PI

- 2010 Research

fund of the

Institute for

the

Research of

the

Influence of

Food on

Human

Health and

Quality of

Life.

200000 NIS

Fatty

liver, adipocytokines an

d nutrition in the

prediction of metabolic

disorders incidence in

the general Israeli

population

Prof. Ran Oren

Roni Lotan

*PI

- 2010 Dr. Sima

Lior Fund.

0000000

NIS

The Role of resistance

training in non


disease, randomized

clinical trial

Prof. Ran Oren *Co-PI

- 2000 Chief

Scientist

Office,

Ministry of

Health.

0060710

The influence of soft

drinks on serum levels

of Advanced Glycation

End Products and

metabolic and

inflammatory markers

Dr. Assy Nimer *Co-PI

16

NIS in patients with non-


- 2010 Chief

Scientist

Office,

Ministry of

Health,

feasibility

study.

000000 NIS

The Role of resistance

training in non


disease, randomized

clinical trial

Prof. Ran Oren *Co-PI

- 2010 Clalit

Health

Services

research

fund.

130,000

NIS.

The prevalence of


fatty liver disease in

low socio-economic

Israeli population, and

the association with

obesity, nutritional

intake and susceptibility

to diabetes

Prof. Ran Oren and

Dr. Hanny Yeshua

*Co-PI

- 2011 The Israel

National

Institute for

Health

Policy and

Health

Services

Research.

150,000

NIS

Trends in serum

25(OH)D distribution in

the Israeli population in

the last decade

Prof. Manfred

Green

*PI

- 2011 Israel

Ministry of

Defence

grant

Non alcoholic fatty

liver disease (NAFLD)

as predictor of diabetes

mellitus, cardiovascular

disease and advanced

liver disease in staff

members of the Israeli

army- long term

prospective follow-up

Dr. Oren Shibolet *PI

17

10. Scholarships, Awards and Prizes

2007 Young investigator award for the best poster, The European Association

for the Study of the Liver. 700 Euro.

11. Teaching

a. Courses Taught in Recent Years

Number of

Students

Degree

B.A./M.A./M.Sc/Ph.D.

Type of Course

Lecture/Seminar/Work

shop

Name of

Course

Year

80 B.A Workshop Nutrition in liver

diseases

2006-

50 None (Ridman" natural

medicine college)

Lectures Medical

nutrition

2007-

2009

8 M.A./M.Sc/Ph.D. Lectures Meta analysis 2008-

20 M.A./M.Sc/Ph.D. Lectures Making sense of

data

2009-

23 M.A./M.Sc/Ph.D. Lectures Nutritional

Epidemiology

2009-

30 M.A./M.Sc/Ph.D. Lectures Construction of

a research

proposal

2009-

10 M.A./M.Sc/Ph.D. Lectures Epidemiology of

cardiovascular

2010-

18

disease

8 M.A./M.Sc/Ph.D. Lectures Applied

research

2010-

b. Supervision of Graduate Students

Student's

Achievements

Date of

Completion /

in Progress

Degree Title of Thesis Name of

Student

- in Progress M.Sc

Incidence of nonalcoholic fatty liver

disease (NAFLD) and

the metabolic syndrome components, a

follow up study

Lotan

Roni*

- in Progress M.Sc

The association between adenomas

and NAFLD

Phlis

Naumi*

- in Progress M.Sc

Physical activity as a treatment for

NAFLD

Buch

Assaf*

- in Progress M.Sc

The association between serum

vitamin D, NAFLD and prediabetes

Edelman

Elena

- in Progress M.Sc

The influence of soft drinks on serum

levels of Advanced Glycation End

Products (AGEs) and metabolic and

inflammatory parameters in patients

with NAFLD

Nseir Hala

- in Progress M.Sc

Knowledge attitudes and practice of

NAFLD patients with

regard to lifestyle modification as

compared to diabetic patients

Dror-Lavi

Gali

- in Progress M.Sc Factors associated with adherence to Ben Abu

19

weight reduction and physical

activity program in obese children

Maya

- in Progress M.Sc

Exposure to passive smoking among

Arab women with acute MI as

compared to controls

Awawdi

Khaled†

- in Progress M.Sc

The association between viral

hepatitis and the metabolic syndrome

Yair-Sabag

Shira

in Progress M.Sc

The association between soft drinks

consumption, serum uric acid and

fatty liver

Openhaimer

Libi

in Progress M.Sc

Knowledge, attitudes and practice

towards soft drinks consumption

among adult Arab population

Jamal

Asuan

in Progress M.Sc

Knowledge, attitudes and

perceptions towards soft drinks

consumption among adult and

pediatric Arab population,

a qualitative research

Abed Petra

90 Graduated MD

research

adviser

Investigating the association between

Hepato-renal index (HRI) and

anthropometric and biochemical

measures among patients of the Fatty

liver clinic

Isaak

Winocur

Michal

*The co-supervisor is Prof. Ran Oren

† The co-supervisor is Prof. Manfred Green

12. Miscellaneous

None

21

PUBLICATIONS

Note: For joint publications, the order of the listed authors appears according to

their relative contribution.

A. Ph.D. Dissertation

Title:

The prevalence of primary nonalcoholic fatty liver disease (NAFLD) in

Israeli population, and the association with biochemical, anthropometric

and nutritional measures.

Date: May 2007

No of pages: 168

Language: English

University: Sackler School of Medicine, Tel Aviv University.

Names of supervisors (Ph.D):

Prof Ran Oren, M.D. Sackler School of Medicine, Tel Aviv University.

Prof Zamir Halpern, M.D. Sackler School of Medicine,

Tel Aviv University.

Dorit Nizan Kaluski, M.D., MPH, R.D. Sackler School of Medicine, Tel

Aviv University.

See publication list: 2, 4, 5, 8.

B. Scientific Books (Refereed)

None

21

C. Monographs - None

D. Articles in Refereed Journals

Published

1. Zelber-Sagi, S., Kessler, A., Brazowsky, E., Webb, M., Lurie, Y, Santo, M.,

Leshno, M., Blendis, L., Halpern, Z., Oren, R. (2006). A double-blind

randomized placebo-controlled trial of Orlistat for the treatment of nonalcoholic

fatty liver disease. Clinical Gastroenterology and Hepatology. (4) 639-44.

IF 5.465

2. Zelber-Sagi, S., Nitzan-Kaluski, D., Halpern, Z., Oren, R. (2006).

Prevalence of primary NAFLD in a population-based study and its association

with biochemical and anthropometric measures. Liver International. (26) 856-

63. IF 2.559

3. Kariv, R., Leshno, M., Beth-Or, A., Strul, H., Blendis, L., Kokia, E., Noff, D.,

Zelber-Sagi, S., Sheinberg, B. Oren, R., Halpern, Z. (2006). Re-evaluation of

serum alanine aminotransferase upper normal limit and its modulating factors in

a large-scale population study. Liver International. (26) 445–50.

IF 2.559

4. Zelber-Sagi, S., Nitzan-Kaluski, D., Halpern, Z., Oren, R. (2007).

NAFLD and serum insulin are major determinants of serum ferritin levels.

Journal of Hepatology. (46) 700-7.

IF 6.642

Received an editorial: Trombini, P., Piperno, A. Ferritin, metabolic syndrome

and NAFLD: Elective attractions and dangerous liaisons. (2007) Journal of

Hepatology. (46) 549-52.

22

5. Zelber-Sagi, S., Nitzan-Kalusky, D., Goldsmith, R., Webb, M., Blendis, L.,

Halpern, Z., Oren, R. (2007). The association between NAFLD and long term

nutritional intake, a population based study. Journal of Hepatology. (47) 711-7.

IF 6.642

6. Lurie, Y., Landau, DA., Kanevsky, A., Pel, S., Zelber-Sagi, S., Oren, R. (2007).

Medex test, a novel modality for liver disease diagnosis: a pilot study. Journal of

Clinical Gastroenterology. (41) 700-5.

IF 0.916

7. Lurie, Y., Landau, DA., Blendis, L., Baruch, Y., Veitsman, E., Ackermann, Z.,

Zelber-Sagi, S., Halpern, Z., Oren, R. (2007). Acute hepatitis C in Israel: a

predominantly iatrogenic disease? Journal of Gastroenterology and Hepatology.

(22) 158-64.

IF 0.983

8. Zelber-Sagi, S., Nitzan-Kaluski, D., Goldsmith, R., Webb, M., Zvibel, I.,

Goldiner, I., Blendis, L., Halpern, Z., Oren, R. (2008). Role of leisure-time

physical activity in non-alcoholic fatty liver disease (NAFLD): A population

based study. Hepatology. (48) 1791-8.

IF 10.734

9. Webb, M., Yeshua, H., Zelber-Sagi, S.*, Santo, M., Brazowski, E., Halpern, Z.,

Oren, R. (2009). The Diagnostic Value of a Computerized Hepatorenal Index for

Ultrasonographic Quantification of Liver Steatosis. American Journal of

Roentgenology. (192) 909-14.

IF 2.47

*The second and third authors contributed equally to the paper.

http://www.ncbi.nlm.nih.gov/pubmed/17667055



23

10. *Ratziu, V., Zelber-Sagi, S. (2009). Pharmacologic therapy of non-alcoholic

steatohepatitis. Review. Clinics in Liver Disease. (13) 667-88.

11. *Zelber-Sagi, S., Ratziu, V., Oren, R. (2011). Nutrition and physical activity in

NAFLD – an overview of the epidemiological evidence. Review. World Journal

of Gastroenterology. (17) 3377-89.

IF 2.24

Received a "Topic highlight":

Nimer, A. (2011). Nutritional recommendations for patients with non-alcoholic

fatty liver disease. World Journal of Gastroenterology. (17) 3375–6.

12. *Zelber-Sagi, S., Yeshua H., Shlomai A., Blendis L., Leshno M., Levit S.,

Halpern Z., Oren R. (2011). Sampling variability of transient elastography

according to probe location. European Journal of Gastroenterology &

Hepatology. (23) 507-14.

IF 1.598

13. *Maharshak N., Halfon P., Deutsch V., Peretz H., Berliner S., Fishman S.,

Zelber-Sagi, S., Rozovski U., Leshno M., Oren R. (2011). Increased fibrosis

progression rates in hepatitis C patients who carry the PTG20210A mutation.

World Journal of Gastroenterology. (17) 5007-13.

IF 2.24

Accepted for Publication

14. *Zelber-Sagi S., Lotan R., Shlomai A., Webb M., Harrari G., Buch A., Nitzan-

Kaluski D., Halpern Z., Oren R. (2011). Predictors for incidence and remission of

NAFLD in the general population during a seven-year prospective follow-up.

Journal of Hepatology.

24

*The first and the second authors contributed equally to the paper.

IF 9.334

15. *Zelber-Sagi S., Ratziu V., Zvibel I., Goldiner I., Blendis L., Morali G., Halpern

Z., Oren R (2011). Can serum leptin and adiponectin predict liver injury in

NAFLD? A study in the general population. European Journal of

Gastroenterology & Hepatology.

IF 1.598

16. *Salamone, F., Volti, GL., Titta, L., Barbagallo, I., Puzzo, L., Zelber-Sagi, S.,

Pelicci, PG., Giorgio, M., Galvano, F. (2011). Moro orange juice prevents fatty

liver in mice. World Journal of Gastroenterology.

IF 2.24

E. Articles or Chapters in Scientific Books

(which are not Conference Proceedings)

None

F. Articles in Conference Proceedings - None

G. Entries in Encyclopedias - None

H. Other Scientific Publications

25

Published

Abstracts Papers Presented at Scientific Meetings, published as


Leshno, M., Blendis, L., Halpern, Z., Oren, R. (2004). A double-blind

randomized placebo-controlled trial of Orlistat for the treatment of nonalcoholic

fatty liver disease. Hepatology. (40) 1069.


Leshno, M., Blendis, L., Halpern, Z., Oren, R. (2005). Does weight loss improve

liver histopathology in patients with NAFLD? Journal of Hepatology. Sup. (42)

705.

3. Kessler, A., Levy, Y., Roth, A., Zelber-Sagi, S., Leshno, M., Blendis,

L.,Halpern, Z., Oren, R. (2005).

Increased prevalence of NAFLD in patients with acute myocardial infarction

independent of BMI. Hepatology (42) 1084.

4. Zelber-Sagi, S., Nitzan-Kalusky, D., Halpern, Z., Oren, R. (2005).

Is NAFLD an independent predictor of the metabolic syndrome?

Hepatology (42) 1069.


Hyperinsulinemia is an independent predictor of elevated serum ALT levels

even after adjustment to NAFLD and liver histology. Hepatology (42) 1081.


Serum ALT is not a reliable screening tool for NAFLD in the general

population. Journal of Hepatology. Sup. 2(44) 727.

7. Zelber-Sagi, S., Nitzan-Kalusky, D., Goldsmith, R., Webb, M., Blendis, M.,

Halpern, Z., Oren, R. (2007). The association between NAFLD and long term

26

nutritional intake, a population based study. Journal of Hepatology. Sup. 1(46)

291.

8. Zelber-Sagi, S., Nitzan-Kalusky, D., Goldsmith, R., Webb, M., Blendis, M.,

Halpern, Z., Oren, R. (2007). Role of physical activity in non-alcoholic fatty

liver disease (NAFLD): A population based study. Hepatology (46) 1150.

9. *Zelber-Sagi, S., Webb, M., Ratziu, V., Poynard, T., Halpern, Z., Oren, R.

(2008). A comparison between the hepatorenal ultrasound index and steatotest

for the non-invasive quantification of liver steatosis. Journal of Hepatology.

Sup. 2(48) 368.

10. Zelber-Sagi, S., Yeshua, H., Halpern, Z., Oren, R. (2009).

Discordance between three successive Fibroscan measurements mirrors the

variability of liver fibrosis. Journal of Hepatology. Sup. 1(50) 375.

11. Zelber-Sagi, S., Ratziu, V., Zvibel, I., Goldiner, I., Nitzan-Kaluski , D., Blendis,

L., Gilles, M., Halpern, Z., Oren, R. (2009).

Can serum leptin and adiponectin predict liver injury in patients with NAFLD? A

study in the general population. Journal of Hepatology. Sup. 1(50) 375.

12. *Zelber-Sagi, S., Webb, M., Leshno, M., Blendis, L., Yeshua, H., Ratziu, V.,

Halpern, Z., Oren, R. (2010). A comparison of fatty liver index with three non-

invasive methods for the detection and Quantification of liver steatosis: Regular

ultrasound, hepatorenal ultrasound index and steatotest. Journal of Hepatology.

Sup. 1(52) 158.

13. *Zelber-Sagi, S., Webb, M., Leshno, M., Blendis, L., Isaak Winocur, M.,

Yeshua, H., Halpern, Z., Oren, R. (2010). The hepatorenal ultrasound index is

correlated with obesity, ALT, insulin and adipocytokines. Journal of Hepatology.

Sup. 1(52) 158.

27

14. *Zelber-Sagi, S., Lotan, R., Webb, M., Halpern, Z., Oren, R. (2011). Incidence

and regression rates of NAFLD in seven years follow up of a cohort from the

general population. Journal of Hepatology. Sup. 1(54) 351.

I. Other Publications

1. Zelber-Sagi, S., Oren, R. Non alcoholic fatty liver disease – the hepatic

manifestation of the metabolic syndrome. Israeli journal of medicine. 8:25-

30, 2007.

2. Zelber-Sagi, S., Oren, R. Non alcoholic fatty liver disease. In: Liver

diseases. Israel: Prolog publishing 2006.

J. Other Works Connected with my Scholarly Field - None

K. Submitted Publications

1. *Zelber-Sagi S., Webb M., Santo E., Blendis L., Yeshua H., Leshno M., Ratziu V.,

Halpern Z., Oren R. A comparison of fatty liver index with three non-invasive methods

for the detection and Quantification of liver steatosis.

28

L. Summary of my Activities and Future Plans

Field of interest and scientific work so far

My research and publications address a wide spectrum of issues regarding non-alcoholic

fatty liver disease (NAFLD) including its prevalence in the general population,

screening methods, independent risk factors and the dual association with the metabolic

syndrome, biochemical characteristics and the association with nutrition and physical

activity.

1. Demonstrating that NAFLD is a prevalent disease in adult Israeli population

with insulin resistance, abdominal obesity and hypertriglyceridemia as

independent risk factors. These results emphasize the crucial role of central

adiposity and the mandatory use of fat distribution indices in metabolic

disorders. Published.

2. Testing issues dealing with ALT, the most specific liver enzyme, including its

value as a screening tool for NAFLD and elaboration of the ALT-insulin

association found in previous epidemiological studies. ALT was not an effective

marker for NAFLD at the population level. In preparation.

3. Since serum ferritin was suggested as one the components of the metabolic

syndrome and is closely associated with NAFLD, we further elaborated this

association by assembling, for the first time, all three variables into the equation.

According to our results, NAFLD may be considered as a possible mediator

between insulin resistance/ metabolic syndrome and serum ferritin levels.

Published.

4. Publishing one of the first epidemiological studies dealing with the

association of NAFLD with long term nutritional intake. Intake of soft

drinks and protein from all kinds of meat was found to be associated with

increased risk for NAFLD and intake of protein from fish rich in omega-3

tended to be associated with a reduced risk for NAFLD. Published.

5. Publishing a paper demonstrating that higher leisure-time physical activity

is inversely associated with NAFLD. This association is independent of

HOMA, nutritional intake, adiponectin and resistin and for resistance

physical activity also of BMI. Published.

29

6. Quantification of liver steatosis is clinically relevant in various liver

diseases, but cannot be done by conventional ultrasound, which only

provides a qualitative assessment with significant observer variability. The

aim of our study was to test whether US can serve as an objective tool for the

quantification of hepatic steatosis by comparing computerized liver

echogenicity to that of the right kidney - hepatorenal ultrasound index (HRI).

We showed that HRI is a sensitive, reproducible, operator independent non-

invasive method for steatosis quantification. Published.

Current scientific projects

1. The incidence of nonalcoholic fatty liver disease (NAFLD) and the

metabolic syndrome components. The aim of our study is to describe the

incidence of NAFLD and the metabolic syndrome components, based on a

follow up of a general Israeli population previously screened for NAFLD. In

preparation.

2. Adipocytokines and FibroMax (a set of biochemical markers for liver

steatosis, inflammation and fibrosis). The aim of this study is to evaluate

whether liver injury in NAFLD can be predicted by serum leptin and

adiponectin. Leptin and adiponectin have been implicated in the development of

hepatic steatosis, inflammation and fibrosis in NAFLD. We found that

Adiponectin and leptin are among the variables most strongly associated with

steatosis and NASH but not with fibrosis. Recently accepted for publication.

3. Discordance between three successive Fibroscan measurements mirrors

the sampling variability of liver fibrosis. Transient Elastography (Fibroscan),

a noninvasive technique, can assess liver fibrosis by measuring liver stiffness

from various liver sites and thus helpful in estimating fibrosis variability.

Almost one third of the patients had some level of discordance between the three

successive Fibroscan measurements. Adopting the maximal or the minimal score

may change dramatically the diagnosis.

31

4. A comparison of fatty liver index with three non-invasive methods for the

detection and quantification of liver steatosis: Regular ultrasound,

hepatorenal ultrasound index and steatotest. The paper deals with the

comparison of different screening tools for fatty liver in the general population.

In preparation.

5. The initiation of a randomized clinical trial - Physical activity as a

treatment for nonalcoholic fatty liver (NAFLD). The effect of different

physical activity regimens will be tested in NAFLD patients with regard to liver

enzymes, metabolic status, body composition and steatosis.

6. The initiation of a controlled clinical trial - The influence of soft drinks on

serum levels of Advanced Glycation End Products (AGEs) and metabolic

and inflammatory parameters in patients with Non-Alcoholic Fatty Liver

Disease. Several patients have been recruited.

7. A case-control study- the association between adenomas and nonalcoholic

fatty liver disease (NAFLD). Data collection is preformed prospectively since

June 2010.

8. Data analysis from the CORDIS (cohort of Israeli employees) data-base with

regard to non-HDL cholesterol and cardiovascular mortality and

hepatocellular carcinoma.

9. Vitamin D and metabolic parameters in the Israeli population– initiating a

study in Macabi health services about the association with NAFLD and pre-

diabetes and the effect of supplementation.

10. Re-evaluation of the normal range of vitamin D with historical cohort of

blood donors with cooperation of the ICDC. Initiation, writing grants and

establishing a research team.

תדריך לעריכת קורות חיים...

Documents